ArticleGenetics in medicine open2023
Carrier screening program for
Article in Genetics in medicine open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant.Breast cancer (Tokyo, Japan) · 2026Article
- Comparative Analysis ofJCO precision oncology · 2026Article
- Psychologically informed reminder messages for promoting BRCA1/2 carrier screening: evidence from a large-scale population-based study.European journal of public health · 2026Observational
- Unique perspectives about men's awareness of BRCA1/2 genetic testing in primary care.Scientific reports · 2026Article
- Optimizing Reporting and Outreach for Surveillance and Risk-Reducing Surgeries for Cancer Genetic Predisposition: Findings of a Workshop Organized by the International Cascade Consortium.Public health genomics · 2026Article
- Clinicopathological features of breast cancer in Ukrainian women with BRCA1 c.181T>G (p.Cys61Gly) variant: a case series.Frontiers in endocrinology · 2026Article
- Identifying a Recurrent BRCA1 Variant in the Qatari Population With Unique Genotype-Phenotype Correlations.Molecular genetics & genomic medicine · 2026Article
- Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer.JAMA network open · 2025Observational
- Large-Scale Population Screening forBreast care (Basel, Switzerland) · 2025Article
- The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024).Journal of medical genetics · 2025Article
- BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.British journal of cancer · 2024Review
- Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.JAMA network open · 2024Article
- The Use of National Cancer Registry Data for Breast Cancer Family History Assessment in Premenopausal Women.Journal of clinical medicine · 2024Article
- Genetic Screening-Emerging Issues.Genes · 2024Review
- Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D.Cancers · 2024Article
- Screening and prevention of ovarian cancer.The Medical journal of Australia · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of the study was to evaluate the results of a large-scale Methods: We performed a cross-sectional study of women who were eligible for Results: The study included 13,502 women who underwent screening between June 2020 and June 2022. The prevalence of the pathogenic variants in Conclusion: The study provides a new insight into a large carrier screening program for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.